Anna Berkenblit

Anna Berkenblit currently serves as the Chief Scientific and Medical Officer at the Pancreatic Cancer Action Network and as an Independent Board Director at Nested Therapeutics and Surrozen. Previously, Anna was the Senior Vice President and Chief Medical Officer at ImmunoGen, Inc., where notable achievements included leading the clinical development of the first-in-class FRalpha ADC for ovarian cancer and advancing the pivekimab sunirine CD123 ADC into pivotal trials. Anna's extensive experience also includes roles as Senior Vice President Head of Clinical Development at H3 Biomedicine, Head of Clinical Research at AVEO, and multiple leadership positions at Pfizer and Wyeth. Educational credentials include a Doctor of Medicine from Harvard Medical School and a Master of Medical Sciences from the Harvard-MIT Division of Health Sciences and Technology, along with a Bachelor of Science in Molecular Biochemistry and Biophysics from Yale University.